Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 315

Similar articles for PubMed (Select 23137508)

1.

Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction.

Bishu K, Deswal A, Chen HH, LeWinter MM, Lewis GD, Semigran MJ, Borlaug BA, McNulty S, Hernandez AF, Braunwald E, Redfield MM.

Am Heart J. 2012 Nov;164(5):763-770.e3. doi: 10.1016/j.ahj.2012.08.014. Epub 2012 Oct 16.

2.

Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction.

Santhanakrishnan R, Chong JP, Ng TP, Ling LH, Sim D, Leong KT, Yeo PS, Ong HY, Jaufeerally F, Wong R, Chai P, Low AF, Richards AM, Lam CS.

Eur J Heart Fail. 2012 Dec;14(12):1338-47. doi: 10.1093/eurjhf/hfs130. Epub 2012 Aug 5.

PMID:
22869458
3.

N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF).

Maeder MT, Rickenbacher P, Rickli H, Abbühl H, Gutmann M, Erne P, Vuilliomenet A, Peter M, Pfisterer M, Brunner-La Rocca HP; TIME-CHF Investigators.

Eur J Heart Fail. 2013 Oct;15(10):1148-56. doi: 10.1093/eurjhf/hft076. Epub 2013 May 8.

PMID:
23657728
4.

Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy.

Krum H, Elsik M, Schneider HG, Ptaszynska A, Black M, Carson PE, Komajda M, Massie BM, McKelvie RS, McMurray JJ, Zile MR, Anand IS.

Circ Heart Fail. 2011 Sep;4(5):561-8. doi: 10.1161/CIRCHEARTFAILURE.110.960716. Epub 2011 Jul 12.

5.

Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND.

Brouwers FP, de Boer RA, van der Harst P, Voors AA, Gansevoort RT, Bakker SJ, Hillege HL, van Veldhuisen DJ, van Gilst WH.

Eur Heart J. 2013 May;34(19):1424-31. doi: 10.1093/eurheartj/eht066. Epub 2013 Mar 6.

6.

Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.

Anand IS, Rector TS, Cleland JG, Kuskowski M, McKelvie RS, Persson H, McMurray JJ, Zile MR, Komajda M, Massie BM, Carson PE.

Circ Heart Fail. 2011 Sep;4(5):569-77. doi: 10.1161/CIRCHEARTFAILURE.111.962654. Epub 2011 Jun 29.

7.

Tricuspid annular plane systolic excursion and pulmonary arterial systolic pressure relationship in heart failure: an index of right ventricular contractile function and prognosis.

Guazzi M, Bandera F, Pelissero G, Castelvecchio S, Menicanti L, Ghio S, Temporelli PL, Arena R.

Am J Physiol Heart Circ Physiol. 2013 Nov 1;305(9):H1373-81. doi: 10.1152/ajpheart.00157.2013. Epub 2013 Aug 30.

8.

Ultrafiltration in heart failure with preserved ejection fraction: comparison with systolic heart failure patients.

Jefferies JL, Bartone C, Menon S, Egnaczyk GF, O'Brien TM, Chung ES.

Circ Heart Fail. 2013 Jul;6(4):733-9. doi: 10.1161/CIRCHEARTFAILURE.112.000309. Epub 2013 Jun 4.

9.

Comparison of characteristics and outcomes of patients with heart failure preserved ejection fraction versus reduced left ventricular ejection fraction in an urban cohort.

Quiroz R, Doros G, Shaw P, Liang CS, Gauthier DF, Sam F.

Am J Cardiol. 2014 Feb 15;113(4):691-6. doi: 10.1016/j.amjcard.2013.11.014. Epub 2013 Nov 23.

PMID:
24484862
10.

Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction.

Lund LH, Benson L, Dahlström U, Edner M.

JAMA. 2012 Nov 28;308(20):2108-17. doi: 10.1001/jama.2012.14785.

PMID:
23188027
11.

Prognostic value of plasma renin activity in heart failure.

Vergaro G, Emdin M, Iervasi A, Zyw L, Gabutti A, Poletti R, Mammini C, Giannoni A, Fontana M, Passino C.

Am J Cardiol. 2011 Jul 15;108(2):246-51. doi: 10.1016/j.amjcard.2011.03.034. Epub 2011 May 3.

PMID:
21545993
12.

Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy.

Schwartzenberg S, Redfield MM, From AM, Sorajja P, Nishimura RA, Borlaug BA.

J Am Coll Cardiol. 2012 Jan 31;59(5):442-51. doi: 10.1016/j.jacc.2011.09.062.

13.

B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction.

van Veldhuisen DJ, Linssen GC, Jaarsma T, van Gilst WH, Hoes AW, Tijssen JG, Paulus WJ, Voors AA, Hillege HL.

J Am Coll Cardiol. 2013 Apr 9;61(14):1498-506. doi: 10.1016/j.jacc.2012.12.044.

14.

Complementary prognostic value of cystatin C, N-terminal pro-B-type natriuretic Peptide and cardiac troponin T in patients with acute heart failure.

Manzano-Fernández S, Boronat-Garcia M, Albaladejo-Otón MD, Pastor P, Garrido IP, Pastor-Pérez FJ, Martínez-Hernández P, Valdés M, Pascual-Figal DA.

Am J Cardiol. 2009 Jun 15;103(12):1753-9. doi: 10.1016/j.amjcard.2009.02.029.

PMID:
19539088
15.

Depressive symptoms are common and associated with adverse clinical outcomes in heart failure with reduced and preserved ejection fraction.

Kato N, Kinugawa K, Shiga T, Hatano M, Takeda N, Imai Y, Watanabe M, Yao A, Hirata Y, Kazuma K, Nagai R.

J Cardiol. 2012 Jul;60(1):23-30. doi: 10.1016/j.jjcc.2012.01.010. Epub 2012 Mar 21.

16.

Role of cardiopulmonary dysfunction and left atrial remodeling in development of acute decompensated heart failure in chronic heart failure with preserved left ventricular ejection fraction.

Kaneko H, Koike A, Senoo K, Tanaka S, Suzuki S, Nagayama O, Sagara K, Otsuka T, Matsuno S, Funada R, Uejima T, Oikawa Y, Yajima J, Nagashima K, Kirigaya H, Sawada H, Aizawa T, Yamashita T.

J Cardiol. 2012 May;59(3):359-65. doi: 10.1016/j.jjcc.2012.01.004. Epub 2012 Mar 14.

17.

Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial.

Jhund PS, Claggett B, Packer M, Zile MR, Voors AA, Pieske B, Lefkowitz M, Shi V, Bransford T, McMurray JJ, Solomon SD.

Eur J Heart Fail. 2014 Jun;16(6):671-7. doi: 10.1002/ejhf.76. Epub 2014 Apr 1.

PMID:
24692284
18.

Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study.

Zakeri R, Borlaug BA, McNulty SE, Mohammed SF, Lewis GD, Semigran MJ, Deswal A, LeWinter M, Hernandez AF, Braunwald E, Redfield MM.

Circ Heart Fail. 2014 Jan;7(1):123-30. doi: 10.1161/CIRCHEARTFAILURE.113.000568. Epub 2013 Oct 25.

19.

Low myocardial protein kinase G activity in heart failure with preserved ejection fraction.

van Heerebeek L, Hamdani N, Falcão-Pires I, Leite-Moreira AF, Begieneman MP, Bronzwaer JG, van der Velden J, Stienen GJ, Laarman GJ, Somsen A, Verheugt FW, Niessen HW, Paulus WJ.

Circulation. 2012 Aug 14;126(7):830-9. doi: 10.1161/CIRCULATIONAHA.111.076075. Epub 2012 Jul 17.

20.

Effects of combined candesartan and ACE inhibitors on BNP, markers of inflammation and oxidative stress, and glucose regulation in patients with symptomatic heart failure.

White M, Lepage S, Lavoie J, De Denus S, Leblanc MH, Gossard D, Whittom L, Racine N, Ducharme A, Dabouz F, Rouleau JL, Touyz R.

J Card Fail. 2007 Mar;13(2):86-94.

PMID:
17395047
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk